0

Psilocybin Could be Key to Helping Millions of People with Eating Disorders

Psilocybin Could be Key to Helping Millions of People with Eating Disorders

With clinical trials supporting psychedelics, like psilocybin mushrooms for the treatment of obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression and anxiety, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines. In fact, in a new study from JAMA Psychiatry, it was found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR. Outside of those issues, psilocybin may also be useful in treating eating disorders. All because psilocybin activates serotonin receptors, or “nature’s own appetite suppressant,” as noted by Psychology Today. “This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight.” With the psilocybin story gaining momentum, some of the top companies to keep an eye on include Better Plant Sciences Inc. (CSE:PLNT)(OTC:VEGGF), HAVN Life Sciences Inc. (CSE:HAVN), Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), Numinus Wellness Inc. (TSXV:NUMI)(OTC:LKYSF), and Mydecine Innovations Group Inc. (CSE:MYCO)(OTC:MYCOF).

Better Plant Sciences Inc. (CSE:PLNT) (OTC:VEGGF) BREAKING NEWS: Better Plant Sciences Inc. is pleased to announce that its partially owned subsidiary NeonMind Biosciences Inc. has successfully completed the maximum offering for its initial public offering of 46,000,000 units of NeonMind at a price to the public of $0.10 per Unit, including 6,000,000 in additional Units pursuant to the exercise in full of the over-allotment option. The gross proceeds from the IPO, before deducting agent fees and estimated offering expenses, were $4.6 million. NeonMind’s common shares were listed on the Canadian Securities Exchange on December 29, 2020 and were immediately halted pending the closing of the IPO. Trading of NeonMind’s common shares on the Exchange will resume at market open on Monday, January 4, 2021 under the ticker symbol “NEON”.

Each Unit consists of one common share of NeonMind and one share purchase warrant to purchase one additional common share of NeonMind at a price of $0.20 per share until December 30, 2021.

Read More

Published at Thu, 31 Dec 2020 14:20:48 +0000

Filed in: News

Get Updates

Share This Post

Recent Posts

© Colorado Medical Marijuana. 2021 All rights reserved .
Home   |   Privacy Policy